The burden of breast, cervical, and colon and rectum cancer in the Balkan countries, 1990-2019 and forecast to 2030.
Journal
Archives of public health = Archives belges de sante publique
ISSN: 0778-7367
Titre abrégé: Arch Public Health
Pays: England
ID NLM: 9208826
Informations de publication
Date de publication:
24 Aug 2023
24 Aug 2023
Historique:
received:
09
03
2023
accepted:
22
06
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
epublish
Résumé
Despite effective prevention and control strategies, in countries of the Balkan region, cancers are the second leading cause of mortality, closely following circulatory system diseases. To describe trends in the burden of breast, cervical, and colon and rectum cancer in the Balkan region and per country between 1990 and 2019, including a forecast to 2030. We described the 2019 Global Burden of Disease (GBD) estimates for breast, cervical, and colon and rectum cancers in eleven Balkan countries over the period 1990-2019, including incidence, years lived with disability (YLD), years of life lost (YLL), and disability-adjusted life years (DALYs) rates per 100,000 population and accompanied 95% uncertainty interval. With the Autoregressive Integrated Moving Average, we forecasted these rates per country up to 2030. In the Balkan region, the highest incidence and DALYs rates in the study period were for colon and rectum, and breast cancers. Over the study period, the DALYs rates for breast cancer per 100,000 population were the highest in Serbia (reaching 670.84 in 2019) but the lowest in Albania (reaching 271.24 in 2019). In 2019, the highest incidence of breast cancer (85 /100,000) and highest YLD rate (64 /100,000) were observed in Greece. Romania had the highest incidence rates, YLD rates, DALY rates, and YLL rates of cervical cancer, with respective 20.59%, 23.39% 4.00%, and 3.47% increases for the 1990/2019 period, and the highest forecasted burden for cervical cancer in 2030. The highest incidence rates, YLD rates and DALY rates of colon and rectum cancers were continuously recorded in Croatia (an increase of 130.75%, 48.23%, and 63.28%, respectively), while the highest YLL rates were in Bulgaria (an increase of 63.85%). The YLL rates due to colon and rectum cancers are forecasted to progress by 2030 in all Balkan countries. As most of the DALYs burden for breast, cervical, and colon and rectum cancer is due to premature mortality, the numerous country-specific barriers to cancer early detection and quality and care continuum should be a public priority of multi-stakeholder collaboration in the Balkan region.
Sections du résumé
BACKGROUND
BACKGROUND
Despite effective prevention and control strategies, in countries of the Balkan region, cancers are the second leading cause of mortality, closely following circulatory system diseases.
OBJECTIVE
OBJECTIVE
To describe trends in the burden of breast, cervical, and colon and rectum cancer in the Balkan region and per country between 1990 and 2019, including a forecast to 2030.
METHODS
METHODS
We described the 2019 Global Burden of Disease (GBD) estimates for breast, cervical, and colon and rectum cancers in eleven Balkan countries over the period 1990-2019, including incidence, years lived with disability (YLD), years of life lost (YLL), and disability-adjusted life years (DALYs) rates per 100,000 population and accompanied 95% uncertainty interval. With the Autoregressive Integrated Moving Average, we forecasted these rates per country up to 2030.
RESULTS
RESULTS
In the Balkan region, the highest incidence and DALYs rates in the study period were for colon and rectum, and breast cancers. Over the study period, the DALYs rates for breast cancer per 100,000 population were the highest in Serbia (reaching 670.84 in 2019) but the lowest in Albania (reaching 271.24 in 2019). In 2019, the highest incidence of breast cancer (85 /100,000) and highest YLD rate (64 /100,000) were observed in Greece. Romania had the highest incidence rates, YLD rates, DALY rates, and YLL rates of cervical cancer, with respective 20.59%, 23.39% 4.00%, and 3.47% increases for the 1990/2019 period, and the highest forecasted burden for cervical cancer in 2030. The highest incidence rates, YLD rates and DALY rates of colon and rectum cancers were continuously recorded in Croatia (an increase of 130.75%, 48.23%, and 63.28%, respectively), while the highest YLL rates were in Bulgaria (an increase of 63.85%). The YLL rates due to colon and rectum cancers are forecasted to progress by 2030 in all Balkan countries.
CONCLUSION
CONCLUSIONS
As most of the DALYs burden for breast, cervical, and colon and rectum cancer is due to premature mortality, the numerous country-specific barriers to cancer early detection and quality and care continuum should be a public priority of multi-stakeholder collaboration in the Balkan region.
Identifiants
pubmed: 37620889
doi: 10.1186/s13690-023-01137-9
pii: 10.1186/s13690-023-01137-9
pmc: PMC10464494
doi:
Types de publication
Journal Article
Langues
eng
Pagination
156Investigateurs
Aaron Liew
(A)
Alexios Fotios Mentis
(AF)
Alibek Mereke
(A)
Ana Catarina Sousa
(AC)
Ana Laura Manda
(AL)
Artemis Gkitakou
(A)
Balazs Adam
(B)
Bogdan Oancea
(B)
Bogdan Socea
(B)
Brigid Unim
(B)
Catalin Gabriel Smarandache
(CG)
Che Henry Ngwa
(CH)
Cornelia Melinda Adi Santoso
(CMA)
Daniel Sur
(D)
Dietrich Plass
(D)
Elena Pallari
(E)
Evangelia Nena
(E)
Federica Gazzelloni
(F)
Florian Fisher
(F)
Francesk Mulita
(F)
Giulia Collatuzzo
(G)
Grant Lewison
(G)
Grant Wyper
(G)
Hanen Samouda
(H)
Ionut Negoi
(I)
Jose Luis Penalvo
(JL)
Juan Manuel Garcia Gonzalez
(JMG)
Juanita Haagsma
(J)
Klara Dokova
(K)
Lazslo Lorenzovici
(L)
Lorenzo Monasta
(L)
Miguel Reina Ortiz
(MR)
Mihaela Hostiuc
(M)
Mika Gissler
(M)
Niko Speybroeck
(N)
Orsolya Varga
(O)
Peter Gaal
(P)
Polychronis Kostoulas
(P)
Ronan O'Caoimh
(R)
Sarah Cuscieri
(S)
Sonia Namorado
(S)
Tomislav Mestrovic
(T)
Vanessa Gorasso
(V)
Vesna Zadnik
(V)
Vildan Mevsim
(V)
Zubair Kabir
(Z)
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
PLoS One. 2021 Jun 24;16(6):e0253373
pubmed: 34166407
BMJ. 2021 May 4;373:n877
pubmed: 33947661
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
MMWR Morb Mortal Wkly Rep. 2014 Nov 7;63(44):1004-9
pubmed: 25375072
Curr Opin Obstet Gynecol. 2016 Feb;28(1):4-10
pubmed: 26642063
Int J Mol Sci. 2017 Jan 19;18(1):
pubmed: 28106826
J Natl Cancer Inst. 2015 May 07;107(6):djv120
pubmed: 25957378
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Lancet Glob Health. 2016 Jul;4(7):e453-63
pubmed: 27340003
Cent Eur J Public Health. 2022 Jun;30(2):119-130
pubmed: 35876601
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99
pubmed: 23199969
Am J Prev Med. 2016 Feb;50(2):241-8
pubmed: 26470806
J Public Health Policy. 2013 May;34(2):272-87
pubmed: 23447031
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Eur J Cancer. 2009 Oct;45(15):2640-8
pubmed: 19695864
Int J Environ Res Public Health. 2020 Jun 28;17(13):
pubmed: 32605159
Front Public Health. 2020 Feb 18;8:29
pubmed: 32133335
Int J Cancer. 2018 Jan 1;142(1):44-56
pubmed: 28940326
Cancer Causes Control. 1997 Sep;8(5):755-63
pubmed: 9328198
Gastroenterology. 2019 Jul;157(1):137-148
pubmed: 30930021
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Lancet Oncol. 2010 Mar;11(3):249-57
pubmed: 20089449